Biopharmaceutical News and Research

RSS

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD.

29 Oct 2012

Range of biopharma solutions from Malvern Instruments extended by distribution agreement with Affinity Biosensors

Materials characterization company Malvern Panalytical. (Malvern Panalytical, UK) has signed an exclusive distribution agreement with Affinity Biosensors LLC (Santa Barbara, CA, USA) which will extend the range of solutions that Malvern Panalytical offers to the biopharmaceutical sector.

From Malvern Panalytical 29 Oct 2012

Exploring the New Biopharmaceutical Contract Manufacturing Offering from Olympus

In this interview, News-Medical talks to Peter Gariepy, to find out about the new Contract Manufacturing Offering (CMO) from Olympus Life Science Solutions.

From Evident Corporation - Life Sciences 25 Oct 2012

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

25 Oct 2012

PLoS ONE publishes review of AntiViral-HyperActivation Limiting Therapeutics clinical trial

ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, announced that a review of the first human clinical trial to test a new class of anti-HIV medications known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) has been published in the peer-reviewed journal PLoS ONE.

22 Oct 2012

BioLineRx completes pre-clinical development of BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.

17 Oct 2012

AAPS recognizes top scientists in pharmaceutical sciences

During the Opening Session of the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, AAPS President David Y. Mitchell, Ph.D., presented the following ground-breaking researchers with awards commemorating their contributions to the pharmaceutical sciences:

15 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

Soluble Therapeutics to introduce high-throughput second viral coefficient determination system

Birmingham-based Soluble Therapeutics, Inc, today announced the official launch of its high-throughput second viral coefficient determination system, HSC Technology, at the IBC BioProcess International Conference in Providence, RI October 8-12.

9 Oct 2012

Liquorice-based nanotech material for sterilizing medical devices

A nanotech material containing an extract from liquorice can be used to sterilize and protect medical devices and implants which include biological components, and protects these functional bio-components during the sterilization process.

8 Oct 2012

Almac signs collaboration agreement with DSM in the field of biocatalysis

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, announced today that it has signed a collaboration agreement with the Almac Group Ltd. (UK) in the field of biocatalysis to provide sustainable manufacturing services to the pharmaceutical industry.

8 Oct 2012

Contract Manufacturing Offering introduced to the biopharmaceutical market by Olympus Biotech

Olympus Biotech, an Olympus Corporation company, today announced its new Contract Manufacturing Offering (CMO) at its state-of-the-art facility in Lebanon, New Hampshire.

From Evident Corporation - Life Sciences 5 Oct 2012

Circassia commences ToleroMune phase 3 trial in cat allergen-induced rhinoconjunctivitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune cat allergy treatment for cat allergen-induced rhinoconjunctivitis.

4 Oct 2012

Cellectis, Medicago complete first step in therapeutic protein research collaboration

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus Like Particles, and Cellectis plant sciences, a US-based subsidiary of Cellectis Group, the specialist in genome engineering, today announced the successful completion of the first step in their research collaboration to improve therapeutic proteins produced in tobacco plants.

4 Oct 2012

Alimera completes $40 million convertible preferred stock sale

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has completed the sale of $40 million of Series A Convertible Preferred Stock and warrants to purchase Series A Preferred to a group of institutional investors, including both existing and new investors, in a private placement.

3 Oct 2012

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of overall survival (OS) data from the trastuzumab emtansine Phase III trial, EMILIA.

2 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

Tianyin Pharmaceutical sales decrease 26.9% to $69.6 million for fiscal year 2012

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2012.

28 Sep 2012

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has amended and expanded the scope of the protocol PV-10-LC-01, "A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant."